Last reviewed · How we verify
NCT06320639: DRIVS-NCD
DRIVing Simulator and People With NeuroCognitive Disorders
trial in Neurocognitive Disorders in 150 participants. Currently enrolling.
10 October 2026
Quick facts
| Lead sponsor | University Gustave Eiffel |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 3 October 2023 |
| Primary completion | 10 October 2026 |
| Estimated completion | 10 October 2026 |
| Sites | 1 location across France |
Conditions studied
- Neurocognitive Disorders — all drugs for Neurocognitive Disorders →
Sponsor
University Gustave Eiffel
Who can join
Adults 50 to 95, any sex, with Neurocognitive Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The ageing of the population is leading to an increasing number of older drivers on the roads. At the same time, the proportion of older people with pathological ageing and neurocognitive disorders (NCD) is increasing. In terms of road safety, this raises the question of whether these drivers should continue to drive or not. People with NCDs may not be aware of the presence, extent and progression of their cognitive impairment and the impact it can have on daily life, including driving. Despite their loss of autonomy and medical advice, 22% of people with major NCD continue to drive. In addition, the presence of minor NCD also puts people at a higher risk of road accidents. However, several studies demonstrated that an NCD does not lead to a systematic and immediate impairment of driving ability and abruptly stopping driving leads to health problems, such as the risk of depression and greatly reduces quality of life. It is therefore relevant to focus research on driving with people with NCD in order to have a reliable indicator of the person's abilities and the impact of their cognitive impairment on driving activity. The proposed study seeks to meet this need by studying the performance of people with NCD on a driving station (mini-simulator) while assessing their ability to evaluate their performance. To achieve this goal, people with NCDs will perform tasks on a driving simulator. In addition, after each task on the driving simulator, they will answer questions about how they evaluate their own driving. Two assessors will observe the participants' driving and will estimate their driving performance. By comparing the driver's self-assessment with the assessors' assessment, an "awareness score of driving ability" will be calculated to determine whether the driver correctly assessed his or her performance. Another project already underway aims to collect similar data from people without a diagnosis of NCDs (control group). The principal objective of the present study is to compare the driving performance in a simulator and the awareness of driving ability of people with NCDs with those of a control group. Secondary objectives are : 1. to measure driving performance in a simulator and awareness of driving abilities (i.e. self-assessment skills) of people with NCDs. 2. to analyse driving performance and awareness of driving abilities according to the diagnosis and severity of the disorder (i.e. minor or major neurocognitive disorders). 3. to establish a methodology to identify a driver at risk of dangerous driving. It is mainly an exploratory study however some hypotheses can be made : * The driving performance and awareness of driving skills of people with NCDs are poorer compared to those of older, control individuals. * Individuals' driving performance and awareness of driving ability are lower in the presence of major NCDs compared to minor NCDs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06320639
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurocognitive Disorders
Currently open trials in the same condition.
- NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting
- NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT06638710 — Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient With Neurocognitive Disorders and · Phase 2 · recruiting
- NCT07048002 — Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06320639 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Gustave Eiffel
- Last refreshed: 20 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06320639.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing